gamma-aminobutyric acid has been researched along with Multiple Myeloma in 4 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway." | 5.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "Multiple myeloma is the cancer of plasma cells." | 5.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway." | 1.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "Multiple myeloma is the cancer of plasma cells." | 1.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "We report a patient affected by restless legs syndrome as the presenting symptom of multiple myeloma, a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow and monoclonal immunoglobulin in the blood and/or urine." | 1.39 | Restless legs syndrome as the presenting symptom of multiple myeloma. ( Aricò, D; Ferri, R; Raggi, A; Siragusa, M; Zucconi, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwaki, K | 1 |
| Fujiwara, T | 1 |
| Ito, T | 1 |
| Suzuki, C | 1 |
| Sasaki, K | 1 |
| Ono, K | 1 |
| Saito, K | 1 |
| Fukuhara, N | 1 |
| Onishi, Y | 1 |
| Yokoyama, H | 1 |
| Fujimaki, S | 1 |
| Tanaka, T | 1 |
| Tamura, H | 1 |
| Fujiwara, M | 1 |
| Harigae, H | 1 |
| Aricò, D | 1 |
| Raggi, A | 1 |
| Siragusa, M | 1 |
| Zucconi, M | 1 |
| Ferri, R | 1 |
| Shahan, JL | 1 |
| Panu, LD | 1 |
| Hildebrandt, GC | 1 |
| Nizeica, V | 1 |
| Collet, P | 1 |
| Marotte, H | 1 |
4 other studies available for gamma-aminobutyric acid and Multiple Myeloma
| Article | Year |
|---|---|
Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Flow Cytometry; gamma-Aminobutyric Acid; Humans; Leukocytes; | 2019 |
Restless legs syndrome as the presenting symptom of multiple myeloma.
Topics: Aged; Amines; Anemia, Iron-Deficiency; Antiparkinson Agents; Benzothiazoles; Cyclohexanecarboxylic A | 2013 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combi | 2012 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid | 2013 |